Aquestive Therapeutics, Inc. AQST Liability related to the sale of future revenue, current
Liability related to the sale of future revenue, current at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current?
- Aquestive Therapeutics, Inc. (AQST) reported liability related to the sale of future revenue, current of $1M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current changed year-over-year?
- Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current decreased by 0.0% year-over-year, from $1M to $1M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current has grown at a 4.1% compound annual growth rate (CAGR), from $922K to $1M.
- What does liability related to the sale of future revenue, current mean?
- This represents the portion of the total liability from the sale of future royalty streams that is due to be settled within the next twelve months. It highlights the immediate cash flow impact of past financing decisions on the company's upcoming liquidity. Tracking this helps investors understand short-term debt service requirements.